Update on Research & Clinical Trials

DelveInsight’s, “Huntington’s Disease Pipeline Insight, 2022,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Huntington’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

In the Huntington’s Disease Pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Huntington’s Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Key takeaways from the Huntington’s Disease Pipeline Report

DelveInsight’s Huntington’s Disease Pipeline analysis depicts a robust space with 50+ active players working to develop 50+ pipeline treatment therapies.
The leading Huntington’s Disease Companies are working such as Prilenia Therapeutics, Ionis Pharmaceuticals, Annexon, Vaccinex, Neurocrine Biosciences, EIP Pharma, SAGE Therapeutics, Celon Pharma, PTC Therapeutics, WaVe life Sciences, Amsterdam Molecular Therapeutics, Novartis, Retrotope, Hope Biosciences, Stealth BioTherapeutics, Luye Pharma Group, Neurimmune Therapeutics, SOLA Biosciences, and others
Promising Huntington’s Disease Pipeline therapies such as Pridopidine, Tominersen, and others.
The companies and academics are working to assess challenges and seek opportunities that could influence Huntington’s Disease R&D. The therapies under development are focused on novel approaches to treat/improve Huntington’s Disease.

Recent Developmental Activities in the Huntington’s Disease Pipeline Report

In August 2018, European Medicines Agency (EMA) granted PRIME (PRIority MEdicines) designation for the tominersen for the treatment of Huntington’s disease (HD). Ionis Pharmaceuticals entered into a collaboration with Roche to develop and commercialize antisense medicines to treat HD in April 2013.
The US FDA granted orphan drug designation to Ionis Pharmaceuticals, for tominersen for the treatment of Huntington’s disease in January 2016.
Pridopidine is a highly selective, first in class small molecule which is sigma-1 receptor (S1R) agonist. Pridopidine is currently in late-stage clinical development for Huntington’s disease. Prilenia has an orphan drug designation for pridopidine for the treatment of Huntington’s disease in both the US and Europe.

Read full article here